SUP-B15 Cells

SUP-B15 is a human B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cell line derived from the bone marrow of a child with Philadelphia chromosome-positive (Ph+) ALL. It is characterized by the presence of the BCR-ABL1 fusion gene, resulting from the t(9;22)(q34;q11) chromosomal translocation, which is a hallmark of Ph+ ALL. This translocation leads to the production of the constitutively active BCR-ABL1 tyrosine kinase, driving leukemogenesis by promoting uncontrolled proliferation and inhibiting apoptosis. As a result, SUP-B15 has been widely utilized in leukemia research, particularly for studying the molecular mechanisms underlying Ph+ ALL and for testing tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib.

Studies have shown that SUP-B15 cells exhibit overexpression of the MDM2 gene, which negatively regulates the tumor suppressor protein p53. This overexpression occurs despite the presence of wild-type p53, suggesting that MDM2-mediated inactivation of p53 contributes to leukemic cell survival. The deregulation of p53 signaling in SUP-B15 and other BCP-ALL cell lines highlights potential therapeutic vulnerabilities, particularly for MDM2 inhibitors that aim to restore p53 function and induce apoptosis in leukemic cells.

Comprehensive genomic and transcriptomic profiling of SUP-B15 has provided additional insights into its molecular landscape. Whole-exome and RNA sequencing studies have identified mutations and gene expression patterns associated with leukemia progression and drug resistance. In pharmacogenomic analyses, SUP-B15 has been included in large-scale drug sensitivity screening efforts, such as those conducted in the Cancer Cell Line Encyclopedia (CCLE). These studies have helped define its responsiveness to various targeted therapies, including TKIs and other small-molecule inhibitors. Given its well-characterized genetic background and clinical relevance, SUP-B15 remains a crucial model for preclinical leukemia research and drug development.